Ironwood sells bio-manufacturing unit; Optimer files for antibiotic approval; ESC action disrupts research projects

@FierceBiotech: Boehringer gets unanimous support for blockbuster stroke drug. News  | Follow @FierceBiotech

 @JohnCFierce: Abbott cuts include Solvay's Marietta, GA pharmaceuticals ops. Article | Follow @JohnCFierce

> Royal DSM has struck a deal to buy Ironwood's Microbia, a bio-manufacturing outfit, for an undisclosed sum. Report

> San Diego-based Optimer Pharmaceuticals has filed for FDA approval of its new antibiotic for Clostridium difficile. The company says that the new antibiotic can cut the reoccurrence rate of the infection almost in half. Story

> Researchers around the country say that the recent courtroom drama around federal ESC subsidies has severely disrupted their work. Story

> NPS Pharmaceuticals says that it raised $44.4 million net from a public offering. NPS has two late-stage registration studies underway. Article

> Dynavax Technologies says that an investment fund has agreed to buy up to $30 million of its shares. News

And Finally... Are consumer tastes dictated by genetics? Researchers found that people like to choose a compromise option and avoid extremes; select sure gains over gambles; prefer an easy but non-rewarding task over an enjoyable challenging one and prefer utilitarian, clearly needed options (like batteries) over more indulgent ones (gourmet chocolate). Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.